Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 3Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 56Stomach Neoplasms 27Pancreatic Neoplasms 18Rectal Neoplasms 16Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 8Colonic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Adenocarcinoma 8Head and Neck Neoplasms 7Gastrointestinal Neoplasms 7Biliary Tract Neoplasms 6Adenocarcinoma Of Esophagus 6Ovarian Neoplasms 5Peritoneal Neoplasms 4Advanced Solid Tumors 4Urinary Bladder Neoplasms 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Breast Neoplasms 3Appendiceal Neoplasms 3Locally Recurrent Rectal Cancer 2

Interventions

pembrolizumab 21enfortumab vedotin 13Gemcitabine 12Nivolumab 8Cisplatin 8Carboplatin 8Magnetic Resonance Spectroscopy 6Specimen Handling 5Docetaxel 5toripalimab 4sacituzumab govitecan 4Paclitaxel 4Ipilimumab 4atezolizumab 3Mitomycin 3Fluorouracil 3disitamab vedotin 2cabozantinib 2avelumab 2Radiosurgery 2Platinum 2Injections 2Immunotherapy 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Biopsy 2zanidatamab 1tremelimumab 1tamibarotene 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Transitional Cell × Fluorouracil × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
60 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡